Latest From AliveCor Inc.
Atrial fibrillation is always a hot topic at cardiology conferences and this year's European Society of Cardiology Congress in Barcelona was no exception. The meeting highlighted data from a spate of key clinical studies providing more insight into this heart condition, including the CASTLE-AF and CAPTAF studies, which further affirmed the benefits of catheter ablation. Outcomes were also reported from REHEARSE-AF and AFFIRM.
Pharma does not need to make wearables. Instead, it needs to figure out how best to use the data that these technologies can provide, how to integrate wearables into product offerings and how to persuade payers to foot the bill. Investment in this field is increasing as the potential of mobile and wearable technologies to transform therapeutic development and healthcare delivery becomes clear.
Patient-centric R&D is imperative for pharma in delivering effective medicines and better outcomes. The push to implement it is challenging long-held biopharma business practices, including how clinical trials are designed, recruited and run – and what they measure.
US Patient Monitoring Devices Market Forecast To Grow $500 Million By 2019 Despite Pricing Pressures, Spending Slowdown
Despite slowdowns in capital equipment spending and strong pricing pressures, the US patient monitoring device market will grow by over $500 million between 2014 and 2019, reaching more than $2.5 billion by 2019 – a CAGR of almost 5%. Several factors are driving growth in this market, including the need for seamless solutions that can provide monitoring from hospital to home, and the growing adoption of portable and wearable technologies.
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AliveCor Inc.
- Senior Management
- Vic Gundotra, CEO
- Contact Info
Phone: (855) 338-8800
140 Geary St.
San Francisco, CA 94108
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.